Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationCurrent Price
as of Oct 18, 2024$295.93
P/E Ratio
N/A
Market Cap
$37.99B
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.
Overview
Trading Information
Company